Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000411097 | SCV000489699 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-11-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001850980 | SCV002243594 | pathogenic | Hereditary breast ovarian cancer syndrome | 2023-05-13 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 372066). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer. (PMID: 28294317, 30702160). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Lys1492*) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). |
Ambry Genetics | RCV002328899 | SCV002636688 | pathogenic | Hereditary cancer-predisposing syndrome | 2017-09-27 | criteria provided, single submitter | clinical testing | The p.K1492* pathogenic mutation (also known as c.4474A>T), located in coding exon 10 of the BRCA2 gene, results from an A to T substitution at nucleotide position 4474. This changes the amino acid from a lysine to a stop codon within coding exon 10. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |